Publication Name	World Journal of Clinical Urology
Manuscript ID	10897
Country	Japan

Received	2014-04-25 11:21
Peer-Review Started	2014-04-29 09:47
To Make the First Decision	2014-05-23 15:12
Return for Revision	2014-05-27 10:16
Revised	2014-06-05 16:19
Second Decision	2014-07-17 14:21
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-07-17 14:39
Articles in Press	2014-07-17 14:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-17 08:40
Publish the Manuscript Online	2014-11-19 17:43

ISSN	2219-2816 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Review
Article Title	Benefits and risks of erythrocyte-stimulating agents
Manuscript Source	Invited Manuscript
All Author List	Daisuke Katagiri and Fumihiko Hinoshita
Funding Agency and Grant Number
Corresponding Author	Fumihiko Hinoshita, MD, PhD, Department of Nephrology, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan. fhinoshi@hosp.ncgm.go.jp
Key Words	Chronic kidney disease; Erythrocyte-stimulating agents; Renal anemia; Erythropoietin; Pure red cell aplasia
Core Tip	Renal anemia is a common clinical problem in patients with severe chronic kidney disease. To overcome the shortage of endogenous erythropoietin (EPO), administration of exogenous EPO is an effective treatment. The advent of recombinant human erythropoietin (rHu-EPO) products has dramatically changed the therapeutic strategy and has shown outstanding effectiveness in patients with renal anemia. Here we discuss the treatment of renal anemia and the adverse effects of rHu-EPO.
Publish Date	2014-11-19 17:43
Citation	Katagiri D, Hinoshita F. Benefits and risks of erythrocyte-stimulating agents. World J Clin Urol 2014; 3(3): 258-263
URL	http://www.wjgnet.com/2219-2816/full/v3/i3/258.htm
DOI	http://dx.doi.org/10.5410/wjcu.v3.i3.258

Full Article (PDF)	WJCU-3-258.pdf
Full Article (Word)	WJCU-3-258.doc
Manuscript File	10897-Review.docx
Answering Reviewers	10897-Answering reviewers.pdf
Copyright License Agreement	10897-Copyright assignment.pdf
Peer-review Report	10897-Peer review(s).pdf
Scientific Misconduct Check	10897-CrossCheck.jpg
Scientific Editor Work List	10897-Scientific editor work list.pdf